TH
vs
S
S&P TSX Composite Index (Canada)
TH
Over the past 12 months, TH has significantly outperformed S&P TSX Composite Index (Canada), delivering a return of +120% compared to the S&P TSX Composite Index (Canada)'s +24% growth.
Stocks Performance
TH vs S&P TSX Composite Index (Canada)
Performance Gap
TH vs S&P TSX Composite Index (Canada)
Performance By Year
TH vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Theratechnologies Inc
Glance View
Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).
